Erratum to “PLGA nanoparticle-integrated microneedles for controlled transdermal delivery of ADT-OH to ameliorate endothelial dysfunction in vitro” [Int. J. Pharm. 690 (2026) 126535] (International Journal of Pharmaceutics (2026) 690, (S0378517325013729), (10.1016/j.ijpharm.2025.126535))

The publisher regrets that the below errors occurred during the publication process of the article. The author affiliations were not correct and should read as indicated above. The following section titles must be updated: 4. Post-Microneedle formulation nanoparticle characterisation needs to be deleted. 4.1 Ex vivo evaluation of transdermal delivery and skin deposition of PLGA-encapsulated ADT-OH via microneedles should be 3.3 Ex Vivo Evaluation of Transdermal Delivery and Skin Deposition of PLGA-Encapsulated ADT-OH via Microneedles 4.2. Post-Treatment with permeate-delivered ADT-OH suppresses inflammation, reduces oxidative stress, and preserves mitochondrial function in TNF-α–Induced endothelial dysfunction should be 3.4 Post-Treatment with Permeate-Delivered ADT-OH Suppresses Inflammation, Reduces Oxidative Stress, and Preserves Mitochondrial Function in TNF-α–Induced Endothelial Dysfunction 4.3 Pro-angiogenic activity of ADT-OH PLGA nanoparticle microneedle formulation should be 3.5 Pro-Angiogenic Activity of ADT-OH PLGA Nanoparticle Microneedle Formulation The publisher would like to apologise for any inconvenience caused.